Bahji Anees
Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Can J Psychiatry. 2025 Feb;70(2):136-137. doi: 10.1177/07067437241312683. Epub 2025 Jan 17.
Plain Language Summary Stimulant addiction, such as addiction to drugs like amphetamines, is a growing public health concern, but there are very few effective medications to treat it. A recent study reviewed a drug called modafinil and found it didn't help reduce drug use, cravings, or improve treatment outcomes. This article discusses why treatments that work for other addictions, like opioids, are less effective for stimulants. It also highlights the challenges researchers face, such as differences in study methods and overlooking common issues like mental health problems or using multiple substances. The focus on complete abstinence as a treatment goal is another issue. Harm reduction, which involves reducing drug use and improving health and social well-being, could be more realistic and beneficial for many people. Finally, while therapy remains the most effective treatment, it's not always accessible. This article calls for new, innovative approaches that prioritize harm reduction, safety, and long-term recovery.
通俗易懂的总结 兴奋剂成瘾，如苯丙胺类药物成瘾，是一个日益严重的公共卫生问题，但治疗该问题的有效药物却非常少。最近一项研究评估了一种名为莫达非尼的药物，发现它无助于减少药物使用、减轻渴望或改善治疗效果。本文讨论了为何对其他成瘾（如阿片类药物成瘾）有效的治疗方法对兴奋剂成瘾效果较差。它还强调了研究人员面临的挑战，如研究方法的差异以及忽视心理健康问题或使用多种物质等常见问题。将完全戒断作为治疗目标也是一个问题。减少伤害，即减少药物使用并改善健康和社会福祉，对许多人来说可能更现实且有益。最后，虽然心理治疗仍然是最有效的治疗方法，但并非总是能够获得。本文呼吁采取新的创新方法，将减少伤害、安全和长期康复作为优先事项。
